Saner Fuat H, Olde Damink Steven W M, Pavlakovic Goran, van den Broek Maartje A J, Rath Peter-Michael, Sotiropoulos Georgios C, Radtke Arnold, Canbay Ali, Paul Andreas, Nadalin Silvio, Malagó Massimo, Broelsch Christoph E
Department of General-, Visceral- and Transplant Surgery, University Hospital Essen, Essen, Germany.
Transplantation. 2008 Jun 15;85(11):1564-8. doi: 10.1097/TP.0b013e31816f61a6.
Infectious complications occur in approximately 50% of cadaveric liver transplant (CDLT) recipients. Living-donor liver transplantation (LDLT) is an established alternative to shorten the waiting time. Currently, the incidence of pulmonary infections after LDLT and the microbiologic causes are unknown. In the present cohort study, we compared the incidence and profiles of pulmonary and blood stream infections (BSI) between LDLT and CDLT recipients. We hypothesized a lower incidence in LDLT recipients.
The clinical course of 55 LDLT recipients consecutively transplanted between January 2003 and December 2006 was analyzed. The 173 CDLT recipients who were transplanted in the same period served as a control group. Patients were treated in a single Intensive Care Unit, applying standardized postoperative care.
Mean model for end-stage liver disease score did not differ between LDLT and CDLT recipients (14.2 vs. 13.3). The overall incidence of pulmonary and BSI for both groups was 8% and 24%, respectively. Pulmonary infections were experienced by 18% of LDLT versus 5% of CDLT recipients (P=0.005) and BSI occurred in 33% of LDLT versus 21% of CDLT recipients (P=0.1).
In contrast to our hypothesis, LDLT recipients experienced significantly more pulmonary infections and a trend toward increased higher incidence of BSI. These findings emphasize the need for future research on the causative agents and prevention of infection in LDLT recipients. The observation that patients with pulmonary infection had a significantly reduced 1-year survival rate underscores the importance of our observations.
约50%的尸体肝移植(CDLT)受者会发生感染性并发症。活体肝移植(LDLT)是缩短等待时间的既定替代方案。目前,LDLT后肺部感染的发生率及微生物学病因尚不清楚。在本队列研究中,我们比较了LDLT和CDLT受者肺部感染和血流感染(BSI)的发生率及特征。我们假设LDLT受者的发生率较低。
分析了2003年1月至2006年12月期间连续接受移植的55例LDLT受者的临床病程。同期接受移植的173例CDLT受者作为对照组。患者在单一重症监护病房接受治疗,采用标准化的术后护理。
LDLT和CDLT受者的终末期肝病平均模型评分无差异(14.2对13.3)。两组肺部感染和BSI的总发生率分别为8%和24%。18%的LDLT受者发生肺部感染,而CDLT受者为5%(P=0.005);33%的LDLT受者发生BSI,而CDLT受者为21%(P=0.1)。
与我们的假设相反,LDLT受者发生肺部感染的情况明显更多,且BSI发生率有升高趋势。这些发现强调了未来对LDLT受者感染病原体及预防感染进行研究的必要性。肺部感染患者1年生存率显著降低的观察结果突出了我们观察结果的重要性。